Programmed Cell Death 1 Receptor
"Programmed Cell Death 1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE.
| Descriptor ID |
D061026
|
| MeSH Number(s) |
D12.776.543.750.705.222.875 D23.050.301.264.894.790 D23.101.100.894.790
|
| Concept/Terms |
Programmed Cell Death 1 Receptor- Programmed Cell Death 1 Receptor
- PD-1 Receptor
- PD 1 Receptor
- Receptor, PD-1
- CD279 Antigen
- Antigen, CD279
- PD1 Receptor
- Receptor, PD1
- Programmed Cell Death 1 Protein
- Antigens, CD279
- CD279 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Receptor".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- Programmed Cell Death 1 Receptor [D12.776.543.750.705.222.875]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- Programmed Cell Death 1 Receptor [D23.050.301.264.894.790]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- Programmed Cell Death 1 Receptor [D23.101.100.894.790]
Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Receptor".
This graph shows the total number of publications written about "Programmed Cell Death 1 Receptor" by people in this website by year, and whether "Programmed Cell Death 1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Programmed Cell Death 1 Receptor" by people in Profiles.
-
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Adv. 2023 Jun 27; 7(12):2670-2676.
-
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer. 2022 01; 10(1).
-
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 09; 35(9):2672-2683.
-
Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
-
Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma. J Surg Res. 2020 12; 256:90-95.
-
Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 2020 01 02; 130(1):451-465.
-
Revving up the immune engine in cHL. Blood. 2019 07 04; 134(1):1-2.
-
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. J Thorac Oncol. 2019 05; 14(5):793-801.
-
Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: An exploratory study. Surgery. 2019 01; 165(1):196-201.
-
Immune Checkpoint Blockade for Breast Cancer. Cancer Treat Res. 2018; 173:155-165.